Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Dirk Schadendorf, Georgina V. Long, Jacob Schachter et al.|The Lancet Oncology|2019

Cited by 56